KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacific Biosciences Of California (PACB) EBITDA (2016 - 2025)

Pacific Biosciences Of California has reported EBITDA over the past 16 years, most recently at -$40.3 million for Q4 2025.

  • Quarterly results put EBITDA at -$40.3 million for Q4 2025, down 3352.34% from a year ago — trailing twelve months through Dec 2025 was -$546.3 million (down 76.44% YoY), and the annual figure for FY2025 was -$546.3 million, down 76.44%.
  • EBITDA for Q4 2025 was -$40.3 million at Pacific Biosciences Of California, down from -$37.9 million in the prior quarter.
  • Over the last five years, EBITDA for PACB hit a ceiling of $1.2 million in Q4 2024 and a floor of -$426.1 million in Q1 2025.
  • Median EBITDA over the past 5 years was -$72.8 million (2022), compared with a mean of -$88.1 million.
  • Biggest five-year swings in EBITDA: crashed 6894.56% in 2021 and later skyrocketed 101.55% in 2024.
  • Pacific Biosciences Of California's EBITDA stood at -$70.4 million in 2021, then fell by 17.67% to -$82.9 million in 2022, then grew by 3.53% to -$80.0 million in 2023, then skyrocketed by 101.55% to $1.2 million in 2024, then tumbled by 3352.34% to -$40.3 million in 2025.
  • The last three reported values for EBITDA were -$40.3 million (Q4 2025), -$37.9 million (Q3 2025), and -$42.0 million (Q2 2025) per Business Quant data.